Meeting
2014 Gastrointestinal Cancers Symposium
Efficacy and safety of FOLFOX biweekly cetuximab as first-line therapy for patients with nonresectable metastatic colorectal cancer (CELINE trial): Multicenter phase II trial.
Authors
Ken Kondo
Ngoya Medical Center, Nagoya, Japan
Ken Kondo , Masanori Kotake , Kenji Doden , Yoshinori Munemoto , Kenji Kobayashi , Genichi Nishimura , Kazuhiko Omote , Junichi Sakamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000006402
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 645)
DOI
10.1200/jco.2014.32.3_suppl.645
Abstract #
645
Poster Bd #
E36
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
A multi-institutional feasibility study of S-1/oxaliplatin (SOX) plus bevacizumab in patients with advanced/metastatic colorectal cancer: HiSCO-02 prospective phase II study.
First Author: Manabu Kurayoshi
Poster
2014 Gastrointestinal Cancers Symposium
A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05).
First Author: Tatsuro Yamaguchi
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2023 ASCO Annual Meeting
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.
First Author: Veronica Conca